Advertisement
Advertisement
Study decoded · health · longevity · Confirmed
Direct AMPK Activator Drug Extends Lifespan In Yeast Worms And Flies
AMPK longevity switch3 species, longer lifeMouse liver proteins shiftDirect vs indirect activationHuman trials not yet done
A compound called 991 that directly switches on the cellular energy sensor AMPK extended lifespan in fruit flies, roundworms and fission yeast, according to a study published September 29, 2026 in Aging Cell.
Researchers tested 991, a drug designed to bind AMPK directly rather than through the indirect, multi-pathway action of metformin, across four model organisms. In fruit flies, dietary 991 extended lifespan compared with untreated controls and lowered whole-body fat (triglyceride) levels in a dose-dependent way, without changing feeding or egg-laying. In roundworms (C. elegans), 991 increased survival on two different bacterial food sources. In fission yeast (S. pombe), it increased survival in a chronological lifespan assay. When researchers deleted the AMPK gene in worms (aak-2 mutants) and yeast (ssp2 mutants), 991 failed to extend lifespan and shortened it in the AMPK-null yeast, showing the effect required AMPK itself. Higher doses shortened lifespan in both flies and worms. In mice given nanoparticle-delivered 991 for 3 weeks, liver protein analysis found a pattern consistent with AMPK activation, including increased ATP-production proteins, suppressed mTOR growth signaling and more mitochondria-building proteins, with survival-related processes the most enriched category.
AMPK acts like a cell's fuel gauge: when energy runs low, it switches on fat-burning and dials back growth-and-repair signaling that competes for the same resources. Because 991 binds AMPK directly in a specific pocket, rather than altering overall cell metabolism the way metformin does, the authors describe this as proof-of-principle that AMPK activation itself can extend lifespan across species.
991 dosing across species
Data Panel
- Who
- Fruit flies (Drosophila), roundworms (C. elegans), fission yeast (S. pombe), and wild-type plus dystrophy-model mice (10 to 18 week old males)
- Design
- Cross-species intervention study: dietary or topical dosing with AMPK-null genetic controls in worms and yeast; mice received nanoparticle-delivered drug for 3 weeks with unbiased liver proteomics, not lifespan tracking
- Dose
- 991 administered in diet to flies and worms and in growth medium to yeast at organism-specific concentrations (10 to 100 micromolar in yeast, 100 micromolar in worm plates); mice received 3.5 mg/kg intravenously 3 times weekly or every other day for 3 weeks
- Primary result
- 991 extended lifespan in flies, worms (both E. coli food sources) and yeast; lifespan extension was abolished in AMPK-gene-deleted worms and yeast, confirming an AMPK-specific effect; exact percentage lifespan change not reported in the available text
- Secondary
- Fly whole-body fat (triglyceride) levels decreased dose-dependently with no change in feeding rate or egg-laying; higher 991 doses shortened lifespan in flies and worms; mouse liver proteomics after 3 weeks showed increased ATP-production proteins, suppressed mTOR signaling, more mitochondria-building proteins, with survival-related processes the top enriched category
- Funding / conflicts
- Funded by the UK Medical Research Council (grants MC-M302-M3410 and MC-M302-M3450), with additional funding from Wellcome Trust/Royal Society, DFG German Research Foundation, Royal Society, BBSRC and Fondation Maladies Rares/AFM Telethon. The authors declare no conflicts of interest.
The mouse portion measured liver protein patterns over 3 weeks, not survival, so no mouse lifespan numbers exist yet. The authors state future mouse work will need oral or dietary dosing and newer AMPK-activating compounds with better absorption, since 991 required nanoparticle injection. No conflicts of interest were declared.
Dr. Axe's Take
A drug that directly flips on AMPK, the cell's fuel gauge, extended life in three separate species and shifted mouse liver proteins toward a longevity pattern in 3 weeks. That is a strong proof of concept for the pathway, not a human treatment, and higher doses shortened life in flies and worms, so dosing matters enormously. I would work this same pathway through habits that activate AMPK naturally: time-restricted eating and resistance training. Both push cells into the same fuel-sensing state this drug targeted, without the dosing risk seen here.
— Dr. Axe